MannKind Corporation (NASDAQ: MNKD)
MannKind has had a rough time in the market as of late, however, the rough time may be coming to an end relatively soon. MNKD announced that it will be giving a presentation at the Aegis Capital Corp. 2015 Growth Conference on Thursday, October 8th at 9:30 am Pacific. However, they haven’t provided any details on what they plan on presenting. So today, we’ll talk about what we’ve seen from MannKind recently, what I think they may be presenting, and what we can expect to see from MNKD moving forward. So, let’s get right to it…
What You Need To Know About MNKD
MannKind is an incredible company that, in my opinion, has come up with a way to revolutionize the treatment of diabetes. That revolutionary invention is called Afrezza. It’s an inhaled insulin that relieves diabetics from having to take a shot before meals.
However, we haven’t seen very much good news since Afrezza was officially approved by the FDA. Unfortunately, sales simply haven’t been what investors were expecting. The reality is that with little to no advertising, consumer awareness simply hasn’t been what it could have been. Nonetheless, the kinks are being worked out with regard to consumer awareness as the Direct to Consumer campaign continues.
Another major issue with sales has been insurance. The bottom line is that the end consumer rarely pays for his medications out of pocket. These days, consumers rely on their insurance coverage to cover the cost of treatments, but Afrezza hasn’t had coverage from any of the major insurance companies. This is also changing. In fact, about 80% of major insurance companies will be covering Afrezza in one way or another relatively soon.
All of that being said, there’s something else that you need to know about MannKind. Investors have paid close attention to Afrezza, and for good reason; it’s the only approved product MNKD has on the market. However, it’s important to note that MannKind has mentioned that it is furthering technosphere and looking to use this proprietary technology in other indications. In fact, a few months ago, MNKD made a big hire just for that reason! This means that some time in the future, we will be hearing that MNKD has another product it intends to bring to the market.
What We Can Expect To See In Thursday’s Presentation
There are two things that I’m expecting to see in Thursday’s presentation from MNKD. One is just about a guarantee, the other wishful thinking. Here’s what I expect…
- Afrezza Updates – First and foremost, I’m looking for a bit of a discussion surrounding Afrezza. After all Afrezza is currently the only bread winner for MNKD. We should be hearing about insurance coverage, marketing campaigns, and possibly even movements toward regulatory approval in Asia and Europe!
- The Next Big Thing – Since there has been no mention of new treatments MNKD is in the process of developing, this is wishful thinking. Nonetheless, as I mentioned above, MNKD made a big hire earlier in the year with regard to advancing its proprietary technology into other indications. It’s possible that the company will make an announcement with regard to projects its working on outside of Afrezza. There has been chatter online about a pain reliever and other possible products. I’m hoping to hear more right from the horses mouth Thursday!
What Do You Think?
What do you think MNKD will be presenting on Thursday? Let us know in the comments below!
[Image Courtesy of The Motley Fool]